BioTelemetry, Inc.
BEAT
BEAT was delisted on the 8th of February, 2021.
1 hedge funds and large institutions have $116K invested in BioTelemetry, Inc. in 2021 Q1 according to their latest regulatory filings, with 0 funds opening new positions, 0 increasing their positions, 1 reducing their positions, and 233 closing their positions.
100% less funds holding
Funds holding: 238 → 1 (-237)
100% less capital invested
Capital invested by funds: $2.3B → $116K (-$2.3B)
100% less funds holding in top 10
Funds holding in top 10: 6 → 0 (-6)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 233
100% less repeat investments, than reductions
Existing positions increased: 0 | Existing positions reduced: 1
Top Buyers
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
-$387M |
| 2 |
ACH
ArrowMark Colorado Holdings
Denver,
Colorado
|
-$283M |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
-$251M |
| 4 |
AAM
Alpine Associates Management
Palm Beach,
Florida
|
-$89.2M |
| 5 |
Dimensional Fund Advisors
Austin,
Texas
|
-$77M |
BEAT Hedge Fund Activity: Q1 2021 in Review
1 of the 5,695 institutional investors tracked by Wall St. Rank reported a position in BioTelemetry, Inc. (BEAT) for Q1 2021, worth a combined $116K — down 100% from $2.3B a quarter earlier.
Sellers outnumbered buyers: 233 funds closed out of BEAT and 0 opened new positions — a net loss of 233 holders — while 1 trimmed existing stakes and 0 added.
The largest seller was BlackRock, exiting entirely with an estimated $387M sold.
- 1 institutional investor held BioTelemetry, Inc. (BEAT) as of Q1 2021, down from 238 in Q4 2020.
- Funds reported $116K of BioTelemetry, Inc. stock for Q1 2021, down 100% quarter-over-quarter.
- 0 funds opened new BioTelemetry, Inc. positions in Q1 2021 and 233 closed out, a net change of -233 holders.
- The largest BioTelemetry, Inc. seller in Q1 2021 was BlackRock, an estimated $387M sold.
Based on aggregated 13F filings for Q1 2021.